| 前收市價 | 387.70 |
| 開市 | 386.60 |
| 買盤 | 389.10 x 0 |
| 賣出價 | 392.10 x 0 |
| 今日波幅 | 386.60 - 393.90 |
| 52 週波幅 | 248.30 - 409.80 |
| 成交量 | |
| 平均成交量 | 13 |
| 市值 | 無 |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | 無 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
ZacksAuto Roundup: KMX's Weak Quarterly Results, TSLA's FSD Price Cut & More
While CarMax's (KMX) fiscal fourth-quarter 2024 earnings and sales miss estimates, Tesla (TSLA) slashes the monthly subscription price of FSD software to half.
- Reuters
UPDATE 1-Agnellis' Exor targets growth in healthcare sector
Exor, the investment arm of the Agnelli family, has a growing interest in the healthcare industry, where it has already invested almost 4 billion euros ($4.3 billion), CEO John Elkann said on Thursday. "The increased cost of healthcare services combined with a shortage of medical staff is driving demand for innovative new approaches to tackle global health problems," he said in his annual letter to Exor shareholders. Exor views healthcare as a "long-term, structural growth sector," added Elkann, the scion of the Agnelli family and chair of automakers Stellantis and Ferrari.
- Reuters
Exor has growing interest in healthcare industry
Exor, the investment arm of the Agnelli family, has a growing interest in the healthcare industry, where it has already invested almost 4 billion euros ($4.3 billion), CEO John Elkann said on Thursday. "The increased cost of healthcare services combined with a shortage of medical staff is driving demand for innovative new approaches to tackle global health problems," he said in his annual letter to Exor shareholders. Exor views healthcare as a "long-term, structural growth sector," said Elkann, the scion of the Agnelli family and chair of automakers Stellantis and Ferrari.
